Compare Gilead Sciences, Inc. (GILD) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs United States Natural Gas Fund — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.40B), while United States Natural Gas Fund trades at $10.74 (market cap $522.93M). The key difference: Gilead Sciences, Inc. is far larger — about 348.8× United States Natural Gas Fund's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while United States Natural Gas Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and United States Natural Gas Fund for 22 Days on average.
| GILD | UNG | |
|---|---|---|
Market Cap | $182.40B | $522.93M |
Volume | 4,469,821 | 33,973,188 |
Sector | Health | Commodities - Energy |
52-Week High | $155.80 | $16.90 |
52-Week Low | $116.74 | $9.63 |
Typical Hold Time | 111 Days | 22 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
UNG trades at $11.03, up 2.7% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported a net income of $65.15 million in 2024, though revenue was $0.00, and maintains a strong balance sheet with total assets of $790.02 million and minimal liabilities. Recent news highlights volatility in natural gas markets due to geopolitical tensions and record U.S. production.
The outlook for UNG is mixed, with bullish technicals and solid profitability offset by revenue uncertainty and market risks. Key opportunities include potential price support from geopolitical events, while risks involve natural gas price fluctuations and high production levels pressuring margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
